EGFR and non-small cell lung carcinoma: Somatic mutations in the EGFR kinase domain and EGFR amplification have been associated with a better response to EGFR-TKIs, such as gefitinib and erlotinib, in patients with NSCLC (Lynch et al, 2004; Paez et al, 2004; Pao et al, 2004; Cappuzzo et al, 2005; Mitsudomi et al, 2005; Takano et al, 2005).